UnknownPhase 3

Low Dose Aspirin for the Prevention of Preeclampsia

Panama476 participantsStarted 2013-07

Plain-language summary

Preeclampsia is one of the three leading causes of maternal morbidity and mortality all over the world. The use of low dose aspirin has been mentioned in several studies with promising results. The investigators decided to evaluate the use of low dose aspirin, starting between 13 and 16 weeks of pregnancy, based on clinical characteristics only to reduce the incidence of preeclampsia.

Who can participate

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Gestational age between 13 and 16 weeks of pregnancy * High risk of preeclampsia, based in clinical risk factors as: Preeclampsia in a previous pregnancy Mother or sister that developed preeclampsia in a previous pregnancy Diabetes Mellitus (insulin dependant) Chronic Hypertension (with/without proteinuria) Body Mass Index \> 32 Multiple pregnancy Lupus or other autoimmune disorder Chronic Renal Disease. Exclusion Criteria: * Blood coagulation disorders of any kind * Peptic ulcers * Allergy to aspirin * Chronic use of anti-inflammatory drugs * Fetus with mayor anomalies

What they're measuring

Prevention of preeclampsia

Timeframe: 6 months

Trial details

NCT IDNCT01890005

SponsorSaint Thomas Hospital, Panama

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-12

Contact for this trial

Rodrigo Velarde, MD

revelarde_14@yahoo.es

View on ClinicalTrials.gov More Preeclampsia trials